(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > Clínica Universidad de Navarra > Oncología médica > DA - CUN - Oncología médica - Artículos de revista >

Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study
Autor(es) : Garcia-Rayo, S. (S.)
Perez-Calvo, J. (Javier)
Martin-Algarra, S. (Salvador)
Martinez-Monge, R. (Rafael)
Fernandez-Hidalgo, Ó. (Óscar)
Subira, L. (L.)
Martinez-Aguillo, M. (M.)
Rebollo, J. (J.)
Azinovic, I. (Ignacio)
Brugarolas, A. (A.)
Palabras clave : Dose-intensity
Breast cancer
Peripheral blood stem cells
Fecha incorporación: 2001
Editorial : Nature
Versión del editor: http://www.nature.com/bmt/journal/v28/n3/pdf/1703125a.pdf
ISSN: 0268-3369
Cita: Garcia-Rayo S, Perez-Calvo J, Martin-Algarra S, Martinez-Monge R, Fernandez-Hidalgo O, Subira L, et al. Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study. Bone Marrow Transplant 2001 Aug;28(3):235-242.
Resumen
The purpose of this trial was to study feasibility and tolerance of a dose-intensive multicyclic alternating induction chemotherapy with repeated stem cell support in a series of 43 metastatic breast cancer patients. Anthracycline-naive patients (n = 21) received cyclophosphamide 2.5 g/m2 plus doxorubicin 80 mg/m2 alternating every 14 days with paclitaxel 200-350 mg/m2 plus cisplatin 120 mg/m2. Patients who had previously received anthracyclines (n = 22) received cisplatin 120 mg/m2 plus etoposide 600 mg/m2 alternating with paclitaxel 200-350 mg/m2 plus ifosfamide 8 g/m2. Peripheral blood stem cells were infused after every course except the first, with a median CD34+ dose of 2.1 ´ 106/kg per cycle. Positive selection of CD34+ cells was performed in good mobilizers. The median number of cycles administered was six (4-8), and the time interval between them was 17 days. Median summation dose intensities (SDI) actually administered for the CA-TP and PE-TI protocol were 4.95 and 4.69, respectively (87% of scheduled SDI). There were 15 complete (35%) and 21 partial responses (49%), for an overall response rate of 84% (95% CI, 73%-95%). Infection or neutropenic fever occurred in 50% of the cycles. There was one treatment-related death. After a median follow-up of 26 months, the median event-free-survival was 12 months (95% CI: 10-14) and overall survival was 31 months. These high dose-intensity induction treatments seem to be feasible with sequential stem cell support.
Enlace permanente: http://hdl.handle.net/10171/22736
Aparece en las colecciones: DA - CUN - Oncología médica - Artículos de revista

Ficheros en este registro:
Fichero:  Bone Marrow Transplant 2001.235.pdf
Descripción: 
Tamaño:  135,94 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.